Versartis Inc., of Redwood City, Calif., said it completed patient enrollment in a Phase I trial of VRS-317, a once-monthly form of recombinant human growth hormone. The primary objective of the study is to evaluate the safety and tolerability of a single subcutaneous dose of the drug.
Suite: 1100 | Atlanta, Georgia 30346, USA
Outside of the US
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
Sign up for Highlights FREE e-mail newsletter